Gilead Sciences and Galapagos NV announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programmes and a proven drug discovery platform. Galapagos will receive a US$ 3.95 billion upfront payment and a US$ 1.1 billion equity investment from Gilead. Galapagos will use the proceeds to expand and accelerate its research and development programmes. Gilead will receive an exclusive product license and option rights to develop and commercialize all current and future programmes in all countries outside Europe. In addition, Gilead and Galapagos have agreed to amend certain terms in the agreement governing filgotinib, the candidate being advanced for rheumatoid arthritis and other inflammatory diseases to provide a broader commercialization role for Galapagos in Europe.